Immunovia AB (publ) (IMMNOV)
Free
No email, no account, no signup.
Pulling latest news for Immunovia AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
NEUTRAL
Sentiment
4/10
Risk
9/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Immunovia AB (publ) develops and commercializes **PancreaSure**, a blood test aimed at early detection of pancreatic cancer in high-risk patients. The company is in an early U.S.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Cancer diagnostics (blood test for pancreatic cancer)
Market Cap
$14M
Market sentiment
Sentiment is **negative to neutral**, dominated by funding/dilution concerns and demand for proof of sales traction. Positive clinical data and the Medicare price are acknowledged, but execution skepticism remains.
Why NEUTRAL ?
- **Promising clinical performance** and a clear addressable market.
- **Revenues remain minimal**, making the equity highly news-driven.
- **High execution risk** in U.S. reimbursement and adoption pathways.
- Estimated runway of ~**9 months** makes 2026 pivotal for traction.
- Wait/hold a small watch position until clear volume growth and improved coverage signals emerge.
Recent News
- Since 2026-04-06, Immunovia published Q1 2026 (revenue SEK 374k; operating result -SEK 18.4m; cash SEK 56.1m; cash burn ~SEK 7m/month). The company launched the ASSURE prospective US registry study (running to early 2029) to build clinical-utility and reimbursement evidence. PancreaSure gained additional state regulatory clearances and is now sold in 49 of 50 states (New York pending). The proposed reverse split was withdrawn after discussions with larger shareholders, and three Strategic Account Managers were recruited to build the US commercial organization.
Bull case
- **Additional state approvals** could quickly expand commercial reach.
- Early **test orders/adoption** from centers could move the stock from depressed levels.
Unlock to read more →
Bear case
- **Low near-term revenue** may amplify funding concerns.
Unlock to read more →
Catalysts
1 Jul 2026 — Clinical utility/registry (~400 pts)
Dilution Risk
Assessment: Medium
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Immunovia AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.